ClinicalTrials.gg
CompletedNCT05226338Updated Aug 8, 2022

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

A Phase 1 interventional study of D-0502 in Healthy Female Volunteer, sponsored by InventisBio Co., Ltd. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects

Read the detailed description

Phase 1, Open Label, Randomized, Single dose, 3 Period, 3 treatment study to evaluation the relative Bioavailability of D-0502 tablet formulation in healthy female subjects

02

Conditions studied

  • Healthy Female Volunteer
03

In context

Lead sponsor

InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female subjects between the ages of 18-55
  • Required evaluation by Investigator for screening and enrollment
  • Agreement and compliance with the study and follow-up procedures

Exclusion criteria

Exclusion Criteria:

  • Significant medical history or current comorbidly determined by the Investigator.
  • Pregnant or nursing women
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Sequence 1

    3 period, 3 dose level

    Drug: D-0502

  • Experimental
    Sequence 2

    3 period, 3 dose level

    Drug: D-0502

  • Experimental
    Sequence 3

    3 period, 3 dose level

    Drug: D-0502

  • Experimental
    Sequence 4

    3 period, 3 dose level

    Drug: D-0502

  • Experimental
    Sequence 5

    3 period, 3 dose level

    Drug: D-0502

  • Experimental
    Sequence 6

    3 period, 3 dose level

    Drug: D-0502

Interventions

  • DrugD-0502

    Formulation 1 Formulation 2 Formulation 3

06

What researchers measure

Primary outcomes

  1. Access the oral bioavailability of D-0502 100mg and 200mg tablets

    Access the oral bioavailability of D-0502 100mg and 200mg tablets relative to D-0502 50mg tablet formulation

    Time frame: Single Dose, 3 period, 3 treatment study separated by 14 day washout periods to evaluate safety and bioavailability. Overall time in study is approximately 42 days.

07

Study locations

1 site
  • Labcorp Clinical Research Unit
    Daytona Beach, Florida 32114, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Feb 7, 2022
StartActual
Oct 27, 2021
Primary completionActual
Dec 23, 2021
CompletionActual
May 11, 2022
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05226338
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Oct 27, 2021
Primary completion
Dec 23, 2021
Completion
May 11, 2022
Last update
Aug 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taragarestrant

Start the discussion